emirates7 - The Department of Health – Abu Dhabi (DoH) has signed a Memorandum of Understanding with Boehringer Ingelheim, a global leader in research-driven pharmaceuticals, to drive forward scientific innovation and research in the Emirate.
This strategic collaboration aims to boost research and development, enhance scientific excellence, and strengthen Abu Dhabi’s position as a leading hub for healthcare, life sciences, and innovation across the MENA region.
The MoU was formalised during the BIO International Convention in Boston at the Abu Dhabi Pavilion, with the signing taking place in the presence of Dr. Noura Khamis Al Ghaithi, Undersecretary of DoH, and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at Boehringer Ingelheim. The agreement was signed by Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at Boehringer Ingelheim.
The partnership will enhance Abu Dhabi’s research landscape by enabling access to Boehringer Ingelheim’s OpnMe platform — a powerful resource offering state-of-the-art data and tools to support scientific breakthroughs and tackle complex biological challenges.
Researchers and innovators across the Emirate will benefit from the platform’s four flagship programmes: Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e), and opnTALENTS (o25). These initiatives provide access to high-quality compounds, promote collaborative research, connect scientists with global experts, and nurture emerging talent.
Dr. Asma Al Mannaei noted that this partnership is part of Abu Dhabi’s broader strategy to lead global health innovation. She highlighted that the OpnMe platform offers researchers open access to advanced pharmaceutical compounds, fosters collaboration, and protects intellectual property, contributing to faster scientific progress and a more resilient future.
Ousama Alhaj added that Boehringer Ingelheim is honored to join forces with DoH to support scientific advancement and empower the next generation of researchers in the region through the OpnMe platform.
This strategic collaboration aims to boost research and development, enhance scientific excellence, and strengthen Abu Dhabi’s position as a leading hub for healthcare, life sciences, and innovation across the MENA region.
The MoU was formalised during the BIO International Convention in Boston at the Abu Dhabi Pavilion, with the signing taking place in the presence of Dr. Noura Khamis Al Ghaithi, Undersecretary of DoH, and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at Boehringer Ingelheim. The agreement was signed by Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at Boehringer Ingelheim.
The partnership will enhance Abu Dhabi’s research landscape by enabling access to Boehringer Ingelheim’s OpnMe platform — a powerful resource offering state-of-the-art data and tools to support scientific breakthroughs and tackle complex biological challenges.
Researchers and innovators across the Emirate will benefit from the platform’s four flagship programmes: Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e), and opnTALENTS (o25). These initiatives provide access to high-quality compounds, promote collaborative research, connect scientists with global experts, and nurture emerging talent.
Dr. Asma Al Mannaei noted that this partnership is part of Abu Dhabi’s broader strategy to lead global health innovation. She highlighted that the OpnMe platform offers researchers open access to advanced pharmaceutical compounds, fosters collaboration, and protects intellectual property, contributing to faster scientific progress and a more resilient future.
Ousama Alhaj added that Boehringer Ingelheim is honored to join forces with DoH to support scientific advancement and empower the next generation of researchers in the region through the OpnMe platform.